Iminothiazolidinones as inhibitors of HCV replication

Details Iminothiazolidinones as inhibitors of HCV replication Iminothiazolidinones as inhibitors of HCV replication

2007-02-27

2007-02-27

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S236800, C514S277000, C514S370000, C514S422000, C544S159000, C544S166000, C546S270700, C548S185000, C548S524000

Reexamination Certificate

active

10637099

ABSTRACT:
Compounds having the structure of formula I are describedwherein R, R′, R1, R2, and R3are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.

REFERENCES:
patent: 6030785 (2000-02-01), Katze et al.
patent: 6323180 (2001-11-01), Llinas-Brunet et al.
patent: 2005/0069522 (2005-03-01), Colonno et al.
patent: WO2001-JP9790 (2001-10-01), None
Lauer et al. (2001) New England Journal of Medicine, vol. 345, No. 1, pp. 41-52.
Poynard et al. (1998) The Lancet, vol. 352, pp. 1426-1432.
Zeuzem et al. (2000) The New England Journal of Medicine, vol. 343, No. 23, pp. 1666-1672.
De Clercq. (2001) Journal of Clinical Virology, vol. 22, pp. 73-89.
Tan et al. (2001) Virology, vol. 284, pp. 1-12.
Park et al. (2003) The Journal of Biological Chemistry, vol. 278, No. 33, pp. 30711-30718.
Sarrazin, C. et al., “Mutations in the Protein Kinase-Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a Are Associated with Treatment Response,” The Journal of Infectious Diseases, vol. 181, pp. 432-441 (2000).
Frangeul, L. et al., “Mutations in NS5A Region of Hepatitis C Virus Genome Correlate With Presence of NS5A Anitbodies and Response to Interferon Therapy for Most Common European Hepatitis C Virus Genotypes,” Hepatology, vol. 28, No. 6, pp. 1674-1679 (1998).
Woitas, R.P. et al., “Differential expansion of T-cell receptor variable beta subsets after antigenice stimulation in patients with different outcomes of hepatitis C infection,” Immunology, vol. 106, pp. 419-427 (2002).
Wang, Y.S. et al., “Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications,” Advanced Drug Delivery Reviews, vol. 54, pp. 547-570 (2002).

Affiliated with

Also associated with

Rating

Iminothiazolidinones as inhibitors of HCV replication does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Iminothiazolidinones as inhibitors of HCV replication, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iminothiazolidinones as inhibitors of HCV replication will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3880685